Indian researchers have developed a 'smart' cancer drug, RK-251, designed to target tumor cells specifically while sparing healthy tissue, potentially replacing traditional chemotherapy.
The drug activates only within the tumor microenvironment, significantly reducing the systemic side effects typically associated with conventional cancer treatments.
Clinical trials are expected to begin soon, offering new hope for patients seeking more precise and less toxic therapeutic options for various cancer types.